Roth Capital Lifts PT on BioLineRx (BLRX) to $10.50 Following Investor Day; BL-8040 in AML Remains Promising
Tweet Send to a Friend
Roth Capital raises its price target on BioLineRx (Nasdaq: BLRX) from $8 up to $10.50 while maintaining a Buy rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
